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Abstract
Background: The management of pediatric recurrent or metastatic soft tissue sarcoma after multimodal treatment
remains challenging. We investigated the feasibility, efficacy, and morbidity of permanent interstitial 125I seed
implantation under image guidance as a salvage treatment for pediatric patients with recurrent or metastatic soft
tissue sarcoma.
Methods: This was a retrospective study of 10 patients who underwent percutaneous ultrasound or computed
tomography (CT) guided permanent 125I seed implantation. Postoperative dosimetry was performed for all patients.
Actuarial D90 was 121–187.1 Gy (median, 170.3 Gy). The number of 125I seeds implanted was 6–158 (median, 34.5),
with a median specific activity of 0.7 mCi per seed (range, 0.62–0.8 mCi); total activity was 4.2–113.76 mCi. Follow-
up time was 6–107 months (median, 27.5 months); no patients were lost to follow-up.
Results: The overall response rate (complete response + partial response) was 8/10 (80 %), including two patients
with complete response (CR) (20 %) and five patients with partial response (PR) (60 %). Local control rates after 1
and 2 years were 70.1 and 62.3 %, respectively, with a mean local control time of 70.6 months (95 % confidence
interval (CI) 45.1–96.0). Survival rates after 1 and 2 years were 68.6 and 57.1 %, respectively, with a mean survival
time of 65.3 months (95 % CI 34.1–96.5). Three patients died from distant metastasis; one died from local recurrence
12 months after seed implantation. Three patients suffered a grade I skin reaction and one developed ulceration.
No severe adverse neurologic sequelae or blood vessel damage occurred.
Conclusions: Image guided permanent interstitial 125I seed implantation as a salvage treatment appears to have a
satisfactory outcome in children with recurrent or metastatic soft tissue sarcoma.
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Background
Soft tissue sarcomas (STSs) are rare mesenchymal tu-
mors that represent 7–10 % of pediatric malignancies
[1]. Although external beam radiotherapy (EBRT) after
surgery has greatly improved local control, a series of
clinical reports indicates that the locoregional recurrence
rate is still about 8–20 % even after such management.
Patients with local recurrence or metastasis of STS
usually have a poor prognosis [1–4]. Recently, new
therapeutic regimens for pediatric recurrent and meta-
static STS have been developed; however, these have not
resulted in favorable local control or survival rates, and
the management of local recurrence and distant metas-
tases thus remains challenging and nonstandardized.
These difficulties are exacerbated by the fact that most
pediatric patients undergo complex multidisciplinary
management including numerous surgical procedures,
radiotherapy, chemotherapy, and various combinations
of these treatments.
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In pediatric patients with recurrent or metastatic STS,
local control may be regained by further surgery with
adequate margins (wide or radical) and EBRT, though
data on the survival benefit are limited. Adjuvant EBRT
is known to be effective in reducing the recurrence rate
[5] but is limited by the tolerance of the surrounding
normal tissues or organs at risk (OARs), which makes it
difficult to achieve a lethal dose to the sarcoma and ul-
timately leads to local recurrence or metastasis. Intersti-
tial implantation of 125I seeds is a promising salvage
therapy for many different recurrent and metastatic ma-
lignant tumors that has been used in, for example, re-
recurrent rectal carcinoma [6], recurrent head and neck
carcinoma [7], and metastatic lymph nodes [8, 9]. Inter-
stitial permanent brachytherapy (BRT) brings new hope
for the treatment of recurrent and metastatic STS in
children because the radiation dose is well localized to
the tumor bed and adjacent uninvolved tissues are
spared [10–16]. However, the literature on experience
with the use of permanent interstitial 125I seeds in
pediatric patients is limited. It is therefore necessary to
investigate the feasibility and efficacy of image guided
permanent implantation of 125I seeds as a salvage ther-
apy for locally recurrent STS in children and to deter-
mine local control, survival, and complications.
Methods
Patient information and selection
We retrospectively analyzed 10 pediatric patients (me-
dian age, 15 years; range, 4–20 years) with recurrence or
metastasis of STS who underwent percutaneous ultra-
sound (color Doppler with probe and guidance
stabilization devices; Aloka 550-5000) or computed tom-
ography (CT) guided permanent 125I seed implantation
at Peking University Third Hospital from December
2005 to March 2014. This study was approved by the
ethics committee in Peking University Third Hospital
and followed the guidelines for experimental investiga-
tion with human subjects required by our institution.
Eligibility criteria were as follows: written informed
consent obtained from parents/guardians before seed
implantation; the recurrent or metastatic tumor diag-
nosed by CT or magnetic resonance imaging (MRI); his-
tologically proven recurrent STS after surgery; EBRT,
chemotherapy, or a combination of these treatments;
Karnofsky Performance Status score 60 or higher; and
no severe dysfunction of the kidneys, liver, or bone mar-
row. Before implantation, the history of all patients was
taken and physical examination, routine hematology and
biochemistry, CT or ultrasonography of the lesions, and
chest radiography were performed. Patients and primary
tumor characteristics are shown in Table 1.
Seven of the 10 patients were boys, and three were
girls. Two patients had re-recurrence after their third
and fourth surgical procedures, respectively. One patient
developed recurrence and metastasis after radical resec-
tion. Two patients who suffered recurrence after surgery
received EBRT (median, 59 Gy; range, 58–60 Gy) but
were re-recurrence. One patient experienced recurrence
after surgery in combination with EBRT at 60 Gy. Two
patients who were deemed unsuitable for surgery when
initially reviewed suffered recurrence after adjuvant
chemotherapy (median, 14 cycles; range, 12–16 cycles)
and EBRT (median, 45.3 Gy; range, 33–57.5 Gy). One
patient with pulmonary metastasis had recurrence dis-
ease after neoadjuvant chemotherapy (4 cycles), radical
resection, EBRT (36 Gy), and adjuvant chemotherapy
(8 cycles). In one patient, recurrence developed
17 months after initial intraoperative 125I seed implant-
ation and subsequent chemotherapy (12 cycles). There
were six cases of distant metastasis among the 10 pa-
tients; these caused mild to moderate pain and limited
movement of the limbs to differing degrees. One patient
Table 1 Patient and primary tumor characteristics (n = 10)
No. of patients Percentage (%)
Age at implant (years)




Pathology of primary tumor
Fibrosarcoma 5 50
Alveolar soft tissue sarcoma 2 20
Primitive neuroectodermal tumor 1 10
Epithelioid sarcoma 1 10
Rhabdomyosarcoma 1 10
Primary tumor stage (AJCC 7th
de, 2010)
I A 3 30




Surgery + EBRT + CTx 1 10
Surgery + EBRT 3 30
Surgery + CTx 1 10
EBRT + CTx 2 20
Surgery 3 30
Follow-up (month)
Median (range) 27.5 (6–107)
Abbreviations: AJCC American Joint Committee on Cancer, EBRT external beam
radiotherapy, CTx chemotherapy
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developed blindness with exophthalmos due to compres-
sion of the right optic nerve by a metastasis. Two pa-
tients had difficulty opening their mouth. The treatment
history before 125I seed implantation for each patient is
listed in Table 2. All of the cases in this study had been
interviewed by surgeons and radiation oncologists who
had considered them unsuitable for salvage surgery and
EBRT or the parents/guardians had refused to undergo
surgery or EBRT.
Pretreatment planning
One to two weeks before seed implantation, a detailed
CT/ultrasound aided tumor volume study was per-
formed for all patients. We obtained CT transverse im-
ages of the targets at 5 mm intervals. The images were
transferred to a three-dimensional radiation therapy
planning system (3D-TPS; Beijing Astro Technology Co.
Ltd, Beijing, China). An experienced radiation oncologist
outlined the gross tumor volume (GTV) and the OARs
on each transverse image. The planning target volume
included the entire GTV with a 0.5–1-cm margin that
was covered by the 90 % isodose curve. The D90
(prescribed dose delivered to 90 % of the target volume)
of seed implant was calculated by the 3D-TPS. The total
number and activity of 125I seeds to be implanted were
determined according to our experience in previous
studies [6–8].
Image guided seed implant protocol
Under adequate local or general anesthesia, five patients
underwent seed implant under CT guidance and the
remainder underwent seed implant under ultrasound
guidance. After the target volume had been determined,
18-gauge needles were implanted into the mass and
spaced at a distance of 1.0 cm in a parallel array, extend-
ing at least 0.5–1.0 cm beyond the margins of the tumor.
The direction of the needles was adjusted to avoid large
blood vessels. The exact puncture process depended pri-
marily on the operator’s experience. 125I seeds (Model
6711; t1/2, 59.4 days; energy, 27.4–31.4 keV; half-value
layer of lead, 0.0025 cm; half-value layer of tissue,
2.0 cm; Beijing Atom and High Technique Industries
Inc., Beijing, China) were implanted using a Mick appli-
cator (Mick Radio-Nuclear Instruments Inc., Mount


















1 F 16 T1aN0M0G1 Fibrosarcoma Right axilla 1 1 60 0 12
Right upper arm
2 M 20 T1aN1M0G1 Fibrosarcoma Left neck and left
supraclavicular




3 F 19 T2bN0M1G2 Fibrosarcoma Maxillofacial and
right eye socket
1 0 0 0 17
4 M 4 T1bN0M0G2 Alveolar soft tissue
sarcoma





5 M 14 T1bN0M0G1 Fibrosarcoma Right shoulder and
neck
1 1 58 0 8
6 M 20 T1aN0M0G1 Fibrosarcoma Right chest wall 4 0 0 0 72
7 M 9 T1bN0M1G3 Primitive
neuroectodermal
tumor
Left mandible 1 0 0 12 17
8 M 16 T2bN1M0G2 Epithelioid sarcoma Right thigh 3 0 0 0 1
9 F 6 T2bN0M1G2 Rhabdomyosarcoma Pelvic 1 1 36 12 1
10 M 11 T2bN1M0G2 Alveolar soft tissue
sarcoma
Right face 0 1 33 12 4
aTumor node metastasis (TNM) stage according to the American Joint Committee on Cancer Staging Manual (2010); bRecurrent time is the interval between seed
implantation and the last treatment
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Vernon, NY, USA), with spaces between seeds (center to
center) of approximately 1.0 cm. The needles were then
removed.
Postimplantation dosimetry
Postoperative dosimetry was routinely performed for all
patients immediately or 24 h after implantation using
three-dimensional seed identification and 5-mm thick-
ness CT scans. The contoured images and sources were
entered into TPS software. Actual isodose distributions
for each slice (Fig. 1) and dose–volume histograms for
the target were generated (Fig. 2). Post-planning evalu-
ation showed the actuarial D90 to be 121–187.1 Gy, with
a median of 170.3 Gy. The number of 125I seeds im-
planted ranged from 6 to 158, with a median of 34.5.
The median specific activity of the 125I seeds was
0.7 mCi per seed (range, 0.62–0.8 mCi). The total activ-
ity was 4.2–113.76 mCi.
Definition of treatment response
Pain intensity was evaluated and graded according to the
Numeric Rating Scale for chronic pain: 1–3 represented
mild pain, 4–6 moderate pain, and 7–10 severe pain [17].
Local tumor response was evaluated by CT 2 months
after seed implantation according to the Response Evalu-
ation Criteria in Solid Tumors version 1.1 (RECIST) [18].
Briefly, complete response (CR) was defined as the
complete disappearance of the lesion, without the appear-
ance of any new lesions and then maintained for 4 weeks.
Partial response (PR) referred to a more than 30 %
decrease in the sum of the largest diameters of target le-
sions. Progressive disease (PD) was defined as at least a
20 % increase in the sum of the largest diameters of target
lesions or the appearance of any new lesions. Stable dis-
ease (SD) was defined as neither sufficient shrinkage to
qualify for PR nor sufficient increase to qualify for PD.
The response rate was equal to the CR + PR.
Complications were scored using the Radiation Ther-
apy Oncology Group (RTOG)/European Organisation
for Research and Treatment of Cancer Late Radiation
Morbidity Score Criteria [19].
Follow-up
Patients were initially evaluated by radiation oncologists
and surgeons 4 weeks after seed implantation and there-
after every 2–3 months, or more frequently if a new
clinical sign or symptom appeared. After 2 years, the pa-
tients were followed-up every 6 months. Patient follow-
up time was calculated from the date of seed implant
and ranged from 7 to 107 months (median, 27.5 months);
no patients were lost to follow-up. Disease status was
assessed by physical examination, liver function tests,
and complete blood and platelet counts. Imaging, in-
cluding CT, MRI, and ultrasonography was used to con-
firm relapse events.
Statistical analysis
Overall survival and local control rates were analyzed
with PASW Statistics version 18.0 using the Kaplan–
Meier method. Survival time was determined from the
date of seed implantation to the date of death or the last
follow-up. Deaths for any reason were scored as events
when calculating survival rates. Local recurrence was
defined as tumor progression within the implanted area




Ten pediatric patients with 12 recurrent and two meta-
static lesions were studied. After seed implant, the inten-
sity of pain decreased to mild pain for the two patients
who had suffered moderate pain and had difficulty open-
ing their mouth. In the patient with exophthalmos, this
was alleviated. One patient with limited right upper limb
outreach recovered completely to normal. However, two
other patients did not experience relief of limb move-
ment restriction (one right upper limb, one right leg).
125I seed treatment details and outcomes are summa-
rized in Table 3.
Tumor local control
The overall response rate (CR + PR) was 8/10 (80 %), in-
cluding two patients with CR (20 %) and five patients
Fig. 1 Isodose curve after seed implantation on a CT scan. The inner
red curve represents the gross tumor volume. The ellipses are isodose
lines of 200, 145, 100, and 45 Gy from inside to outside, respectively
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with PR (60 %). One of the 10 patients had stable disease
(SD; 10 %) and one had progressive disease (PD;10 %).
Local control rates after 1 and 2 years were 70.1 and
62.3 %, respectively, with a mean local control time of
70.6 months (95 % confidence interval (CI) 45.1–96.0)
(Fig. 3).
Overall survival
Survival rates after 1 and 2 years were 68.6 and 57.1 %,
respectively, with a mean survival time of 65.3 months
(95 % CI 34.1–96.5) (Fig. 4). At the time of writing, three
of the patients had died from multiple metastasis; one
patient died from local recurrence 12 months after seed
implantation. Six patients were still alive with no evi-
dence of local recurrence or distant metastases.
Toxicity and complications
Three patients suffered a grade I skin reaction that pre-
sented with local pigmentation after seed implantation.
One patient developed an ulceration associated with dis-
ease progression and died due to pulmonary metastasis
6 months after seed implantation. No seeds were found
Fig. 2 Dose–volume histogram for the target
Table 3 Treatment characteristics of 125I seed implantation and outcomes (n = 10)












1 Yes 4.0 × 2.9 × 2.2 CDU 0.7 33/164.5 No CR – 107 Survival
1.3 × 1.5 × 1.0 CDU 0.7 6/148.1 No CR –
2 Yes 4.0 × 3.6 × 1.8 CDU 0.8 50/172.7 Seed implant after progress PR 24 70 Survival
2.5 × 2.0 × 2.0 CDU 0.7 8/169.4 No PR –
1.8 × 1.2 × 1.0 CDU 0.65 9/171.6 No PR –
3 Yes 6.6 × 7.8 × 9.5 CT 0.72 158/187.0 No PR 12 14 LR
4 No 3.2 × 3.3 × 1.5 CDU 0.7 30/176.0 No CR – 62 Survival
3.4 × 3.0 × 1.2 CDU 0.77 35/166.1 No CR –
5 No 3.2 × 2.9 × 2.0 CDU 0.8 54/174.9 No PR – 51 Survival
6 No 4.0 × 2.0 × 3.0 CDU 0.62 40/121.0 No PR – 41 Survival
7 Yes 3.8 × 3.5 × 3.0 CT 0.72 34/167.2 EBRT (50Gy) SD 8 12 MM
8 Yes 3.5 × 4.9 × 12 CT 0.72 157/171.2 No PR 3 6 MM
9 Yes 3.6 × 2.0 × 3.0 CT 0.66 27/132.0 No PD 3 6 MM
10 No 5.8 × 2.8 × 5.0 CT 0.68 86/187.1 No PR – 7 Survival
Abbreviations: CDU color Doppler ultrasound guided, CT computed tomography guided, EBRT, external beam radiotherapy, RR response rate, CR complete
response, PR partial response, SD stable disease, PD progressive disease, m months, LR local recurrence, MM multiple metastasis
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to have migrated. No adverse neurologic sequelae or
blood vessel damage occurred. No serious RTOG grade
IV late complications were observed.
Discussion
EBRT plays an important role in the treatment of STS in
children. Radiotherapeutic approaches include EBRT,
BRT, and intraoperative radiotherapy. However, EBRT
can cause severe complications in the pediatric popula-
tion, including growth retardation and effects on organ
function. Although there are no randomized clinical tri-
als comparing the curative effect of EBRT and BRT in
patients with recurrent STS, theoretically, compared
with EBRT, BRT has several advantages for pediatric pa-
tients with recurrent and/or metastatic STS after surgi-
cal resection. Due to its radiobiologic characteristics,
BRT can deliver higher doses of radiation to the area
most susceptible to recurrence while delivering a lower
dose to the normal tissues surrounding the target. Fur-
thermore, BRT enables a short overall treatment time,
and the rate of local control is comparatively high. Given
the data in the literature, we can conclude that BRT is
generally the only radiotherapeutic option available
when high grade STS recurs in a previously irradiated
area [13–15, 20–22].
BRT usually involves the temporary or permanent sur-
face, intracavitary, or interstitial application of radioiso-
topes. Many types of BRT are being investigated,
including interstitial high dose rate BRT (HBRT), low
dose rate brachytherapy (LBRT), intraoperative HBRT,
and combinations of these modalities. However, no clin-
ical trial has compared HBRT with LBRT for recurrent
STS. In some pediatric cases, HBRT with 192Ir has been
used either alone or in combination with EBRT in the
management of STS and has been shown to provide
good local control and overall survival rates. Gustavo et
al. [16] reported their experience of treating STS with
HBRT alone or in combination with EBRT in 18
pediatric patients (age, 2–16 years; median, 11 years)
who had intermediate to high grade tumors at the time
that HBRT was performed. With a median follow-up of
79.5 months (range, 12–159 months), overall survival
rates at 5 and 10 years were 84.4 and 72.4 % and the
overall local control rates for the HBRT group (eight
cases) and the HBRT plus EBRT group (10 cases) were
100 and 90 %, respectively. Merchant et al. [10] previ-
ously reported that, for pediatric patients with STS, BRT
was an excellent treatment option. In their study, 31 pa-
tients of median age 11 years (range, 1–21 years) were
managed with BRT initially or at the time of recurrence
Fig. 3 Actuarial local control curve for the 10 patients
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using 125I or 192Ir in a temporary or permanent manner.
At the time of follow-up, 25 patients were alive, with a
median survival time of 34 months.
In the present study, all patients were treated with
interstitial permanent implantation of 125I seeds. Inter-
stitial 125I seed implantation is a method of LBRT that
for many years has been a gold standard prostate BRT in
low risk patients. 125I seeds implanted in a tumor con-
tinuously emit low dose X-rays and γ-rays; during the
half-life of 125I, they deliver a dose of 160–180 Gy to the
local tissues, sparing adjacent normal structures and
medical personnel. This slow emission allows any nor-
mal tissue that does receive a sublethal or potentially le-
thal dose of radiation to repair and recover [23]. Also,
continuous low dose irradiation may reduce the oxygen
enhancement ratio, which may improve the efficacy of
the treatment in hypoxic portions of the tumor [24]. In
addition, the therapeutic benefit may theoretically be
enhanced by natural increases in local dose after
radiation-induced tumor shrinkage brings the 125I seeds
closer together [25]. Finally, permanent interstitial 125I
seed implantation is a quick, 1 day therapy with a low
complication rate both during and after the procedure
[6–9]. Taking all of these benefits into account, perman-
ent 125I seed implantation may be well suited for the
management of pediatric STS, especially in patients with
recurrence and/or metastasis who have already received
multimodal treatment.
Hentz and Barrett [26] reviewed eight pediatric pa-
tients with rhabdomyosarcoma who were treated with
temporary LBRT using 125I, with promising results. The
local recurrence rate was 12.5 % after treatment, and the
side effects were endurable, especially in patients who
had no prior history of irradiation. Zhang et al. [27] re-
ported a total survival rate of 88 % in eight children dur-
ing a median follow-up of 43 months. Li et al. [28]
demonstrated that when a combination of 125I seeds and
an artificial prosthesis was used to replace tumor tissue
in three patients, limb function recovered well. The pa-
tients remained disease-free for 14–18 months and ex-
perienced no severe complications such as infection or
wound bleeding.
The success of 125I BRT mainly depends on the precise
location of the implant needles. In the present study,
125I seed implant was guided by CT or ultrasound,
which ensures accurate placement of seeds within a
known volume of tumor [29, 30]. Optimization of seed
distribution and dose homogeneity can easily be
achieved by adjusting the position of each needle and
seed during implant according to the pretreatment plan.
Fig. 4 Actuarial survival curve for the 10 patients
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In this respect, 125I seed implantation is a safe radiother-
apy and delivers more conformal radiation. However,
few authors have reported on percutaneous seed im-
plantation as a sole therapy for recurrent or metastatic
STS under image guidance, especially in pediatric
patients. In the present study, we performed permanent
interstitial 125I seed implantation as a salvage therapy for
pediatric recurrent and metastatic STS. Our results
demonstrate satisfactory tumor local control and overall
survival rates. Organ function and cosmetic appearance
were maintained and uncompromised.
Conclusions
Image guided permanent interstitial 125I seed implant-
ation as a sole salvage modality is a feasible, minimally
invasive treatment for pediatric recurrent or metastatic
STS, with few complications. It avoids the morbidity as-
sociated with further surgery or EBRT and achieves high
survival and local control rates with endurable toxicity.
The long-term results of this promising procedure with
a greater number of cases are needed to reach a definite
conclusion.
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